Delivers up-to-date industry news on topics like drug approvals, product recalls, company expansions and acquisitions, market trends for all OSD forms, as well as excipients, packaging and supply chain issues. Monitors market trends in specific drug categories as well as in supplements/nutraceuticals. Provides updates on clinical trials. Includes alerts about new or upcoming regulatory issues.
DT120 is a lysergamide compound — an LSD derivative — administered as a single 100 µg orally disintegrating tablet.
read more
The company's proprietary drug delivery platform replaces daily pills with a once-monthly capsule that releases a stable dose.
read more
Complicated urinary tract infections have historically required IV treatment when standard oral options fail.
read more
The acquisition gives Lilly a pipeline of orally-available MNK inhibitors for treating chronic pain.
read more
The drugmaker will advance elecoglipron into an extensive phase 3 program in obesity and type 2 diabetes.
read more
While the board searches for a permanent successor, Albert Manzone will act as interim president and CEO.
read more
Navacaprant failed to lead to improvement compared to a placebo.
read more
The regimen treats virologically-suppressed patients who have switched from Biktarvy.
read more
The cuts will mostly affect the TAPI division in Israel and will roll out over the next two years.
read more
The Boston biotech has two oral kinase inhibitors already under FDA review.
read more
In a phase 3 trial, the drug met its primary endpoint and showed a safety profile consistent with that observed in adults.
read more
Lilly shared phase 3 data for its once-daily GLP-1 tablet, Foundayo, across a broader set of patient populations than its approved obesity indication.
read more
The letter did not raise any concerns regarding the clinical safety or efficacy of CTx-1301.
read more
Rezdiffra is the first approved oral treatment for metabolic dysfunction-associated steatohepatitis in both the U.S. and UK.
read more
The deal centers around Edgewise’s sevasemten, an investigative orally administered first-in-class fast skeletal myosin inhibitor.
read more